HKEx Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Aug
18
INSIDE INFORMATION - PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD.* FOR THE HALF YEAR ENDED 30 JUNE 2019
Aug
15
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF CLINICAL TRIAL APPLICATION FOR INVESTIGATIONAL FIRST-IN-CLASS NEW DRUG ALMB-0166 IN AUSTRALIA
Aug
07
DATE OF BOARD MEETING
Jul
29
VOLUNTARY ANNOUNCEMENT - NEW TARGET ANTI-TUMOR DRUG "SYHA1807" WAS GRANTED CLINICAL TRIAL APPROVAL
Jul
12
INSIDE INFORMATION - ANNOUNCEMENT ON THE INDICATIVE RESULTS FOR THE HALF YEAR ENDED 30 JUNE 2019 OF CSPC INNOVATION PHARMACEUTICAL CO., LTD.*
Jul
12
CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF STEAM SUPPLY AGREEMENT
Jul
02
CHANGE OF ADDRESS OF SHARE REGISTRAR AND TRANSFER OFFICE
Jun
25
CONNECTED TRANSACTIONS - LEASE AGREEMENTS
Jun
13
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "TICAGRELOR TABLETS"
Jun
10
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "CLOPIDOGREL BISULFATE TABLETS"
May
27
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 27 MAY 2019
May
21
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
May
21
CHANGE OF VICE-CHAIRMAN AND ROTATING CHIEF EXECUTIVE OFFICER
May
21
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2019
May
08
DATE OF BOARD MEETING
May
07
VOLUNTARY ANNOUNCEMENT - FORMATION OF JOINT VENTURE
Apr
28
INSIDE INFORMATION - PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD .* FOR THE THREE MONTHS ENDED 31 MARCH 2019
Apr
25
VOLUNTARY ANNOUNCEMENT - "PACLITAXEL CATIONIC LIPOSOME FOR INJECTION" FOR THE TREATMENT OF BREAST CANCER WAS GRANTED CLINICAL TRIAL APPROVAL
Apr
25
VOLUNTARY ANNOUNCEMENT - NEW ORAL ANTI-COAGULANT DRUG "SYHA136" WAS GRANTED CLINICAL TRIAL APPROVAL
Apr
17
NOTICE OF ANNUAL GENERAL MEETING
Apr
12
VOLUNTARY ANNOUNCEMENT - "SYHA1803" FOR THE TREATMENT OF INTRAHEPATIC CHOLANGIOCARCINOMA AND UROTHELIAL CARCINOMA WAS GRANTED CLINICAL TRIAL APPROVAL
Apr
12
VOLUNTARY ANNOUNCEMENT - "SYHA1402" FOR THE TREATMENT OF DIABETIC NEUROPATHY WAS GRANTED CLINICAL TRIAL APPROVAL
Mar
21
UPDATES ON THE SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE CHINEXT OF SHENZHEN STOCK EXCHANGE
Mar
18
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2018
Mar
06
DATE OF BOARD MEETING
Mar
05
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NDA TO U.S. FDA FOR LEVOAMLODIPINE MALEATE TABLETS
Mar
05
PROGRESS UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE SHENZHEN STOCK EXCHANGE
Mar
03
PROGRESS UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE SHENZHEN STOCK EXCHANGE
Feb
26
VOLUNTARY ANNOUNCEMENT - PRODUCT CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTS
Jan
15
GRANT OF SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
Jan
10
UNUSUAL PRICE AND TRADING VOLUME MOVEMENT
Jan
07
VOLUNTARY ANNOUNCEMENT - ACQUISITION OF 100% INTEREST IN YONG SHUN TECHNOLOGY DEVELOPMENT LIMITED
Jan
04
VOLUNTARY ANNOUNCEMENT - PRODUCT CO-DEVELOPMENT AND STRATEGIC COLLABORATION AGREEMENT

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2019 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer